1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: EUDRACT 2004-001647-30, PHRC/04-04, CIC0203/043, NCT00287105
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BDE28, NCT00372476
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BDE57, NCT00427583
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C2454, NCT00510354
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NILG-ALL 10/07, NCT00795756
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: III-MK-CML-IV, EU-20248, NCT00055874
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-62024, ISG-62024, FRE-FNCLCC-EORTC-62024, GEIS-EORTC-62024, EUDRACT-2004-001810-16, NCT00103168
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 030482, NCT00219739
|
|
9.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0502, S0502, CALGB-S0502, CAN-NCIC-S0502, NCT00324987
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CSTI571AAT06, NCT00327262
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 59
Sponsor: Other
Protocol IDs: GRAALL 2005, NCT00327678
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CST1571BFR14, ET2002-021, NCT00367861
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181112, NCT00372567
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: SHEBA-06-4015-IH-CTIL, NCT00297570
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3160A4-3000, NCT00574873
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107DBR01, NCT00751036
|
|
17.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2405, NCT00760877
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107G2301, NCT00785785
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAMN107A2404, NCT00802841
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AB04030, NCT00812240
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: NCI
Protocol IDs: FHCRC-1581.00, 5235, NCI-H02-0087, NCT00036738
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0272, N0272, NCT00049127
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FRE-FNCLCC-SARCOME-05/0401, EU-20515, NCT00287846
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSTI571BIT06, NCT00417807
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CR0506PI, REC:05-054, NCT00558961
|
